Opinion|Videos|December 13, 2023
SAPHYR Trial: Sarilumab’s Impact on Refractory Polymyalgia Rheumatica
Robert Spiera, M.D., discusses the SAPHYR trial, assessing sarilumab’s efficacy in treating refractory polymyalgia rheumatica.
Advertisement
Episodes in this series
This is a video synopsis/summary of a Between the Lines involving Robert Spiera, M.D., and Dana McCormick, R.Ph.
Dana McCormick, R.Ph., and Robert Spiera, M.D., discuss the SAPHYR trial evaluating sarilumab for polymyalgia rheumatica. Focused on steroid-sparing efficacy, the trial targeted tough-to-treat patients, aiming for sustained remission over a year. The study, utilizing sarilumab, involved rapid steroid tapering and a placebo group on a standard taper. The goal was sustained remission by week 52, with stringent criteria including C-reactive protein normalization and no flares post week 14. Secondary outcomes included glucocorticoid dose, flare time and safety. Patient-reported quality-of-life assessments were crucial for this lesser-known disorder, aiding differentiation from other inflammations. Understanding the trial’s design and outcomes sheds light on sarilumab’s potential as a significant therapy. Such insights into effective treatments are vital for optimizing care and improving the lives of patients with polymyalgia rheumatica, a condition often misconstrued among inflammatory diseases.
This summary was AI-generated and reviewed by Managed Healthcare Executive® staff.
Advertisement
Related to this article
Expect Democrats to flex their oversight powers even if President Donald Trump’s veto power blocks their efforts to reverse Medicaid cuts or restore enhanced ACA subsidies. The administration’s most-favored-nation policies and HHS Secretary Kennedy will probably be in the hot seat.
Health plans should be using data, digital tools and human support to identify potential disruptions early, and whether a member is changing plans or managing a new health condition, the experience should feel guided rather than overwhelming.
Pretax adjusted income from operations from Express Scripts, Cigna's pharmacy benefit manager, fell by 21.5% compared with the third quarter of 2025, while income from operations of its specialty drug business jumped by 15%.
Annesha White, Pharm.D., M.S., Ph.D., and Fredrick Manasseh, Pharm.D., MBA, BCGP, explain where AI helps managed care pharmacy, where bias creeps in and what skills pharmacists need to oversee it.
Teva’s Weltruza delivers olanzapine monthly under the skin, with no loading doses, oral supplementation or post-injection monitoring required.
Value-based care has scored some cost-saving successes, says Christopher Stanley, M.D., MBA, president of Henry Ford Health's Populance. Health systems that build their own value-based care strategy, rather than adopting particular models one by one, will be in the best position to succeed, he says.
The second half of our conversation with Christopher Stanley, M.D., MBA, the president of Henry Ford Health's Populance and the newest member of the Managed Healthcare Executive editorial advisory board.
The first part of our conversation with Christopher Stanley, M.D., MBA, the president of Henry Ford Health's Populance and the newest member of the Managed Healthcare Executive editorial advisory board.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
WHO adds two Bundibugyo vaccines to Ebola trial in the DRC
2
8 takeaways from the MHE and Drug Topics post-midterms webinar
3
Cigna’s third-quarter earnings show a drop in income from its pharmacy benefit business
4
On the advantages of health system-owned health plan, what Medicaid cuts might mean and the future of U.S. health insurance: A conversation with Geisinger's Jeremy Gaskill
5